| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
Form 4: Pande Atul, Director
Received 3,000 shares by exercise or conversion ($25.3K) · Sold 3,000 shares ($108K) |
| 12 Nov 2026 | 144 |
| 09 Nov 2026 | S-3ASR |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
DURHAM, N.C. November 9, 2026 – Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its second ... |
| 30 Oct 2026 |
Form 4: Girao Tiago, Chief Financial Officer
Sold 6,606 shares ($188K) |
| 23 Oct 2026 |
Form 4: Stout Jay S, Chief Technology Officer
Sold 2,595 shares ($75.1K) |
| 09 Oct 2026 |
Form 4: Stout Jay S, Chief Technology Officer
Sold 3,809 shares ($122K) |
| 09 Oct 2026 |
Form 4: Van Tuyl Christopher, Chief Legal Officer
Sold 1,327 shares ($42.5K) |
| 09 Oct 2026 |
Form 4: Gloria Melanie, Chief Operating Officer
Sold 2,241 shares ($71.8K) |
| 05 Oct 2026 |
Form 4: Venker Eric, Director
Received 92,187 shares by exercise or conversion ($1.33M) · Returned 85,886 shares to the issuer ($2.89M) · Sold 3,506 shares ($120K) |
| 25 Sep 2026 |
Form 4: Van Tuyl Christopher, Chief Legal Officer
Sold 2,846 shares ($103K) |
| 03 Sep 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On September 2, 2026, Immunovant, Inc. (“Immunovant”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). There were 198,373,370 shares of common stock and Series A preferred stock represented at the Annual Meeting by va... |
| 28 Aug 2026 |
Form 4: Pande Atul, Director
Received 1,500 shares by exercise or conversion ($12.6K) · Sold 1,500 shares ($64.9K) |
| 21 Aug 2026 |
Form 4: Gloria Melanie, Chief Operating Officer
Sold 3,056 shares ($135K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
DURHAM, N.C. August 6, 2026 – Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its first fis... |
| 24 Jul 2026 |
Form 4: Pande Atul, Director
Received 1,500 shares by exercise or conversion ($12.6K) · Sold 1,500 shares ($59.7K) |
| 24 Jul 2026 |
Form 4: Girao Tiago, Chief Financial Officer
Sold 6,798 shares ($263K) |
Loading...